One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...
TipRanks on MSN
Vertex price target lowered to $25 from $32 at Baird
Baird lowered the firm’s price target on Vertex (VERX) to $25 from $32 and keeps a Neutral rating on the shares. The firm updated its model ...
Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...
Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback